Browse all 5 CVE security advisories affecting Illumina. AI-powered Chinese analysis, POCs, and references for each vulnerability.
Illumina specializes in genetic sequencing technology and analysis tools, primarily serving healthcare and research sectors. Historically, their systems have faced vulnerabilities including remote code execution, cross-site scripting, and privilege escalation, often stemming from web application flaws and insufficient input validation. While no major public security incidents have been widely documented, the presence of five CVEs indicates ongoing security challenges. Their complex software ecosystems and integration with sensitive genomic data necessitate robust security measures, particularly as cyber threats to critical infrastructure and research institutions increase.
| CVE ID | Title | CVSS | Severity | Published |
|---|---|---|---|---|
| CVE-2022-1521 | 3.2.4 IMPROPER ACCESS CONTROL CWE-284 — NextSeq 550DxCWE-284 | 9.1 | Critical | 2022-06-24 |
| CVE-2022-1524 | 3.2.5 CLEARTEXT TRANSMISSION OF SENSITIVE INFORMATION CWE-319 — NextSeq 550DxCWE-319 | 7.4 | High | 2022-06-24 |
| CVE-2022-1518 | 3.2.2 IMPROPER LIMITATION OF A PATHNAME TO A RESTRICTED DIRECTORY ('PATH TRAVERSAL') CWE-22 — NextSeq 550DxCWE-22 | 10.0 | Critical | 2022-06-24 |
| CVE-2022-1519 | Illumina Local Run Manager 代码问题漏洞 — NextSeq 550DxCWE-434 | 10.0 | Critical | 2022-06-24 |
| CVE-2022-1517 | 3.2.1 EXECUTION WITH UNNECESSARY PRIVILEGES CWE-250 — NextSeq 550DxCWE-250 | 10.0 | Critical | 2022-06-24 |
This page lists every published CVE security advisory associated with Illumina. Each entry links to a detailed page with CVSS scoring, CWE classification, affected products and references. AI-generated Chinese analysis is provided for fast triage.